PDCD1 and non-small cell lung carcinoma: Five of these studies, all retrospective analyses, mostly encompassing patients with advanced NSCLC, analyzed the associations between administration of anti-PD-1 targeted immunotherapy (nivolumab or pembrolizumab), development of IRAEs and treatment efficacy (52–56).